Liver Cancer :: Nexavar approved for patients with inoperable liver cancer
Anticancer drug Nexavar raised survival period in inoperable hepatocellular carcinoma patients suffering from this kind of liver cancer. The U.S. Food and Drug Administration has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma, a form of kidney cancer.